Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Intoducing cellenONE: The revolutionary Single Cell isolator
May 25, 2022
A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
May 4, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
Introducing Celloger Mini Plus: Automated and compact Live cell imaging inside your incubator
Apr 11, 2022
We are happy to introduce new Celloger Mini Plus, automated live cell imaging system! Click the video below to find out...
CQ1 live-cell confocal system: revealing the pathophysiology of COVID-19 infection
Mar 21, 2022
Yokogawa decided to support the world’s fight against COVID-19, scientifically cooperating with research facilities...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Molecular imaging study design basics
Jan 31, 2022
By combining study design, study management, and image analytics in all major imaging modalities, BioLaurus has...
Oct 20, 2016
Baseline angiogenesis and apoptotic activities were simultaneous evaluated before initiation of the treatment (D0) using the Bruker In-Vivo Xtreme imaging system, after i.p. administration of Angiosense680 EX and Annexin750 probes, respectively, according to the instructions of the supplier. After 3 days of treatment (D3), angiogenesis and apoptotic activities were similarly assessed; GLPG1790, Flavopiridol or Bevacizumab treatments were given 2hr prior to imaging.
All images were captured by a cooled CCD camera with the following parameters: f-stop 1.1, binning 2, 2 sec acquisition time for Angiosense680 EX and 5 sec acquisition time for Annexin750.
For anatomical co-registration, a reflectance image (0.1 second acquisition time, f-stop 2.8, binning 1) and an X-ray image (1.2 second acquisition time, f-stop 4, 45 KVP energy, 2 mm filter) were performed.
For precise co-registration, all images were taken with a 190 mm field of view (FOV). For each mouse and each probe, results were expressed as the difference between Net intensity at D3 and D0.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/